Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Uveal Melanoma and Gq-Pathway Modulator Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GNAQ drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GNAQ (WT & Mutants Q209L, R183C) Recombinant Proteins High purity (>95%), Endotoxin Controlled. Sequence Verified. E. coli/Sf9 expressed. |
View GNAQ Products |
| Gene Delivery | GNAQ Promise-ORF / Lentivirus Full-length ORF (WT and Q209L/R183C mutants) for stable cell line generation. |
View GNAQ Products |
| Benchmark Ab | Anti-GNAQ Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View GNAQ Products |
| Validator | GNAQ siRNA Set For target knockdown and pathway specificity verification. |
View GNAQ Products |
| Related Target A | GNA11 Highly homologous G-protein alpha subunit; frequently co-mutated or redundant in uveal melanoma. |
View GNA11 Products |
| Related Target B | PRKC (PKC) Downstream effector kinase; primary therapeutic target for GNAQ-driven signaling bypass. |
View PRKC Products |
| Related Target C | PLCB4 Phospholipase C beta 4; immediate downstream effector of GNAQ, mutated in a subset of uveal melanomas. |
View PLCB4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Distinguishing WT GNAQ from oncogenic mutants (Q209L, R183C) | Mutant-specific recombinant proteins strictly verified by Mass Spectrometry and sequence analysis. |
| Assessing nucleotide exchange (GDP/GTP binding) | Highly stable, monomeric GNAQ proteins optimized for nucleotide-binding assays. |
| Lack of reliable positive controls | Sequence-verified clinical benchmark antibodies and high-affinity detection reagents. |
| Off-target screening against homologous G-proteins | Complete G-alpha subfamily panel (GNA11, GNAQ, GNAS, GNAI) for counter-screening. |
Live GNAQ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GNAQ has shifted from indirect downstream pathway inhibition to direct, state-specific G-protein modulation. Activating mutations in GNAQ (primarily Q209 and R183) are the molecular drivers in over 80% of uveal melanomas and blue nevi, as well as Sturge-Weber syndrome. Historically, clinical strategies focused on blocking downstream effectors like PKC (e.g., darovasertib) or MEK. However, monotherapy resistance has accelerated the development of direct Galpha q/11 inhibitors and novel combination regimens.
The next wave of drug discovery is focused on small molecules that lock GNAQ in its inactive GDP-bound state or disrupt its interaction with downstream effectors like PLCβ. Additionally, targeting GNAQ-mutant cells via synthetic lethal screens and PROTAC-mediated degradation represents a highly promising frontier in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Direct Galpha q/11) | FogPharma, Ideaya Biosciences, AstraZeneca | Uveal Melanoma, Sturge-Weber Syndrome | GTPase & Nucleotide Exchange Assays (Requires high-purity WT/Mutant GNAQ proteins) |
| Small Molecule (PKC Inhibitors) | Ideaya Biosciences (Darovasertib) | Metastatic Uveal Melanoma | Combination screening & resistance modeling (Requires GNAQ stable cell lines via Lentivirus) |
| PROTAC / Degraders | Academic institutions, Biotech startups | GNAQ-mutant solid tumors | Target ubiquitination and degradation assays (Requires sequence-verified GNAQ-tagged proteins) |